🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  2. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  3. RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe, RO4893594

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  4. RO4893594, RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe

    Hoffmann-La Roche

    Neovascular age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  5. RO7435846, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, PEMETREXED, Budenofalk 3mg magensaftresistente Hartkapseln, CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT D

    Hoffmann-La Roche

    Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. RO7790121 Placebo, RO7790121

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  7. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  8. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  9. RTX-GRT7039, Naropin® 5 mg/ml Injektionslösung

    Gruenenthal GmbH

    Moderate to severe pain associated with Osteoarthritis of the knee

    phase 3 small molecule active

    1 trial

  10. Rabies Vaccine (Serum-free Vero Cell), Freeze-dried

    Sinovac Research and Development Co.,

    Rabies

    phase 3 mab active

    2 trials

  11. Rabies vaccine

    Sinovac Research and Development Co.,

    Rabies (Healthy Volunteers)

    phase 3 mab active

    1 trial

  12. Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).

    The George Institute

    Rabies

    phase 3 small molecule active

    1 trial

  13. Raloxifene - Usual

    Lxo Ireland Designated Activity Company

    Breast Cancer

    phase 3 small molecule active

    1 trial

  14. Raltegravir

    United Therapeutics Europe Ltd

    Human Immunodeficiency Virus

    phase 3 small molecule completed

    1 trial

  15. Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Gastrointestinal Cancers

    phase 3 small molecule active

    1 trial

  16. Ramelteon

    Takeda

    Sleep Initiation and Maintenance Disorders

    phase 3 small molecule completed

    2 trials

  17. Ramelteon SL

    Takeda

    Acute Depressive Episode

    phase 3 small molecule terminated

    1 trial

  18. Ramelteon SL

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  19. Ramelteon SL (Dose 1)

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  20. Randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 other active

    1 trial

  21. Ranibizumab

    Hoffmann-La Roche

    Neovascular Age-related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  22. Ranibizumab

    Regeneron UK Limited

    Macular Degeneration

    phase 3 small molecule completed

    2 trials

  23. Rapastinel

    Allergan Pharmaceuticals International Limited

    Depressive Disorder, Major

    phase 3 small molecule terminated

    1 trial

  24. Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules

    Gedeon Richter Plc.

    Adolescent Patients (13 to 17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources